Blog

On the entire day from the donor stem cell infusion, her DSA amounts continued to drop to bad (Desk 1). cells, refractory ML-3043 B-ALL sufferers may reap the benefits of combination therapy with daratumumab even now. We need further scientific observation. Keywords:severe lymphoblastic leukemia, haploidentical stem cell transplantation, donor-specific anti-HLA antibodies, daratumumab == Launch == Acute lymphoblastic leukemia (ALL) is certainly an extremely heterogeneous disease with a higher threat of relapse, because of high-risk cytogenetic abnormalities13 mainly. Allogeneic hematopoietic stem cell transplantation (allo-HSCT), specifically the individual leukocyte antigen (HLA)-matched up sibling donors (MSDs) and matched up unrelated donors (MUDs), can be an essential option for preventing ALL recurrence4. The limited option of MUDs and MSDs limits the acceptance of allo-HSCT for everyone patients5. Haploidentical stem cell transplantation (haplo-SCT) is becoming an important substitute strategy for such sufferers6,7. Nevertheless, the donor-specific anti-HLA antibodies (DSA) are believed an important hurdle for the effective engraftment of donor stem cell. Id of DSA is among the essential causes of major graft failing (PGF) in haplo-SCT and other styles of HLA-mismatched donor transplantation810. These antibodies are believed to truly have a weakened to low degree of mean fluorescence intensity (MFI) if the values range from 1,000 to 3,000; moderate-level MFI, values from 3,000 to 5,000; and strong-level MFI, values >5,00011. Several desensitization strategies have been used to decrease the total antibody load of DSA to reduce the Bmp7 risk of PGF: plasmapheresis or immunoabsorption, monoclonal antibody to CD20+ B lymphocytes (rituximab), inhibitors against antibody-producing plasma cells (bortezomib), intravenous immunoglobulins, donor HLA antigen (platelet or white blood cell) infusions, and inhibition of complement cascade12. These desensitization strategies have been used in solid organ transplantation and allo-HSCT1315. They improved ML-3043 the risk of PGF and the survival rate of patients in transplantation of partially mismatched hematopoietic stem cell donors. Here we present a patient with refractory B-cell ALL, with strongly positive DSA levels, directed against donor HLA antigens. Before her haplo-SCT, we chose daratumumab combined with chemotherapy for this patient, and she achieved a significant decrease in DSA levels and complete remission (CR). == Medical History Presentation == A 36-year-old female patient was diagnosed with common B-cell ALL. After one course of VDCLP (vincristine, daunorubicin, cyclophosphamide,l-asparaginase, and prednisolone), two cycles of CAM (cyclophosphamide, cytarabine, and 6-mercaptopurine), and two courses of high-dose methotrexate combined with venetoclax chemotherapy, her disease did not achieve CR with 30.36% leukemia cells in the bone marrow (BM) by flow cytometry (FCM) (Fig. 1A). Except for a daughter haploid donor, she had no sibling donor and HLA-matched or HLA-mismatched unrelated donor for her allo-HSCT. Unfortunately, strong MFI level values were found in her DSA test (immunomagnetic beads liquid chip technology) (Table 1). In addition, her ABO ML-3043 blood group could not be detected because of the loss of erythrocyte antigen expression. == Figure 1. == Immunophenotype of leukemia cells by FCM before and after combination therapy with daratumumab. (A) Before daratumumab: Malignant B lymphocytes characterized as CD19+CD22+CD34+CD10dim and CD20CD38 by FCM. (B) After daratumumab: She achieved CR with CD19CD22CD34+CD10CD20CD38 by FCM. FCM: flow cytometry; CR: complete remission. == Table 1. == Change in DSA Levels After Daratumumab Therapy. DSA: donor-specific anti-HLA antibodies; HLA: human leukocyte antigen; Immunoglobulin: intravenous immunoglobulin, 1g/kg; MFI: mean fluorescence intensity of microbead reaction. The bold-faced indicates a different match between the patient and the donor. Although CD38 expression on leukemia cells was negative, daratumumab (16 mg/kg) combined with etoposide and venetoclax therapy was chosen for her. After one cycle of combination therapy, she achieved CR with a significant decrease.